Skip to content

The efficacy of intranasal naloxone in pediatric opioid overdose patients

Intranasal versus intravenous administration of naloxone in pediatric opioid poisoned patients, A pilot randomized clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120629010133N7
Enrollment
40
Registered
2023-06-06
Start date
2021-01-16
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overdose, opioids, Children, Antidote, Naloxone, Intranasal. Poisoning by narcotics and psychodysleptics [hallucinogens]

Interventions

Intervention group:.

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 12 Years

Inclusion criteria

Inclusion criteria: Age more than 1 and less than 12 Opioid poisoning Respiratory depression Miotic pupils Unarousable as defined by Glasgow Coma Score (GCS) = 12/15

Exclusion criteria

Exclusion criteria: Still conscious on ED arrival time Patients that have received naloxone in any form in the previous 24 hours Referral cases with unknown drug intervention Patients who have been referred with IV access Presentation with apnea Nasal congestion No parental deferred consent provided GCS < 7/15 History of drug hypersensitivity relevant to naloxone Co-ingestion of other drugs Intubation before recruitment major facial trauma Epistaxis Negative urine screening test for opioids A clinical condition (such as abnormal liver function; respiratory, renal or cardiac issues) which, in the opinion of the examining medical practitioner, makes participation in the study inappropriate.

Design outcomes

Primary

MeasureTime frame
Proportion of patients with return of spontaneous respiration (above minimum respiratory rate in each age group per minute). Timepoint: On arrival and within 3 minutes of naloxone administration, then each 4 hours. Method of measurement: Measuring the number of respiration in a minute.

Secondary

MeasureTime frame
Time it takes to place IV cannula. Timepoint: From start of procedure till the end (ready for intravenous use). Method of measurement: Measured by stopwatch (per second).;Level of consciousness. Timepoint: Before intervention, 3 minute after intervention, then each 4--hour. Method of measurement: Using Glascow Coma Scale.;O2 saturation before and after naloxone administration. Timepoint: Before intervention, 3 minute after intervention, then each 4--hour. Method of measurement: Using pulse oxymeter.;Increased pCO2. Timepoint: Before intervention, 3 minute after intervention, then each 4--hour. Method of measurement: Using blood gas machine.;Need for a rescue opioid antidote in ED and afterward. Timepoint: During ED admission or afterward till discharge. Method of measurement: Record each dose naloxone, route of administration and time given during admission.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Hassanian-Moghaddam

Shahid Beheshti University of Medical Sciences

hassanian@sbmu.ac.ir+98 21 2274 9201

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026